Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59M
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
65M
-
Shares change
-
+75.1K
-
Total reported value, excl. options
-
$1.09B
-
Value change
-
-$1.27M
-
Put/Call ratio
-
0.19
-
Number of buys
-
82
-
Number of sells
-
-45
-
Price
-
$16.74
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q3 2024
159 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65M shares
.
Largest 10 shareholders include MPM BIOIMPACT LLC (7.65M shares), BVF INC/IL (5.75M shares), BlackRock, Inc. (4.34M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.28M shares), VANGUARD GROUP INC (3M shares), STATE STREET CORP (2.34M shares), Paradigm Biocapital Advisors LP (2.32M shares), FRANKLIN RESOURCES INC (2.19M shares), Blue Owl Capital Holdings LP (2.01M shares), and CITADEL ADVISORS LLC (1.96M shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.